The Translarna Deep Dive will provide an overview of results from the clinical and real-world data generated to date for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in patients 2 years and older. PTC will also review Translarna’s commercial success and the potential regulatory milestones in the United States. As a reminder, the results from Study PTC124-GD-045-DMD will be available in the first quarter of 2021.
The webinar can be accessed by dialing (877) 303-9216 (domestic) or (973) 935-8152 (international) 5 minutes prior to the start of the webinar and providing the passcode 9694665. A live, listen-only webcast can be accessed on the Events and Presentations page under the investor relations section of PTC Therapeutics’ website. A webcast replay will be available approximately 2 hours after completion of the webinar and will be archived for 30 days following the webinar.
[Source(s): PTC Therapeutics Inc, PR Newswire]
Related Content:
Grant Funds Next Step in Study to Assess Duchenne Progression Via Biomarkers
PPMD Presents 1-Year Newborn Duchenne Screening Project Update
FDA Fast-Tracks Duchenne Gene Therapy
